A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.
Jonathan Welte
Advertisement
With Simon-Kucher & Partners’ life sciences division
Articles by Jonathan Welte
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Fayuvi for Pediatric Patients with Sanfilippo Syndrome Type A
2
M&A Roundup: Lisata Therapeutics Acquires Marea Therapeutics, mAbxience Enters Collaboration with Sandoz
3
Why Executive MFN Deals Aren't Enough: Q&A with Joe Cunningham
4
Understanding the Latest with MFN Pricing and What It Means to Pharma
5